Driving with Parkinson’s disease: exploring lived experience – Holmes JD, Alvarez L, Johnson AM, Robinson AE, Gilhuly K, Horst E, Kowalchuk A, Rathwell K, Reklitis Y, Wheildon N.

Driving with Parkinson’s disease: exploring lived experience – Holmes JD, Alvarez L, Johnson AM, Robinson AE, Gilhuly K, Horst E, Kowalchuk A, Rathwell K, Reklitis Y, Wheildon N.

Publication date: Mar 13, 2019

OBJECTIVE: We analyzed the relationship between functional impairment and cognitive performance and its related subdomains in individuals with Parkinson’s disease, Alzheimer’s disease accompanied by motor dysfunction, and with other neurological disorders characterized by both motor and cognitive problems. The scope of treatment applications is also broadening from chronic pain to include cerebral ischemia, dystonia, tremor, multiple sclerosis, Parkinson disease, neuropsychiatric disorders, memory, addiction, cognitive function, and other neurologic diseases. An understanding of the supraspinal mechanisms underlying the beneficial effects of spi. .. Researchers decode how cancer drug works in brains of Parkinson’s disease patients (Georgetown University Medical Center) The first arm of a phase II clinical trial by a research team at Georgetown University Medical Center testing the use of nilotinib in patients with Parkinson’s disease demonstrates precisely how the agent increases levels of dopamine in the brains of study and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson’s disease AbstractNilotinib is a broad -based tyrosine kinase inhibitor with the highest affinity to inhibit Abelson (c-Abl) and discoidin domain receptors (DDR1/2). Successful treatment with antidepressants and other therapies had been linked. .. Source: Proceedings of the National Academy of Sciences – Category: Science Authors: Tags: Core Concepts, Front Matter Source Type: research Parkinson’s disease warning – the hidden sign of brain condition in your nose revealed PARKINSON ‘S disease symptoms develop slowly over a long period of time, and are caused by nerve damage in the brain.

Concepts Keywords
Addiction Parkinson s disease
Affinity Pain
Alzheimer Chronic pain
AM Inflammation
Antidepressants Slow movement tremors
Brain Surgical treatment
Cerebral Ischemia Branches of biology
Chronic Pain Medicine
Cingulate Health
Clinical Trial Psychiatric diagnosis
Cognitive RTT
Cognitive Function Aging-associated diseases
Cognitive Impairment Neurological disorders
Dementia Cognitive disorders
Depression Parkinson’s disease
Divalent Nilotinib
Dopamine Alzheimer’s disease
Dystonia Synucleinopathy
Fitness Alpha
Georgetown Pharmacodynamics
Inflammation
JD
Lewy Bodies
Manganese
Memory
Misfolding
Movement Disorders
Multiple Sclerosis
Nerve
Neurodegenerative Condition
Neurodegenerative Disorders
Neurologic Diseases
Neurological Disorders
Neurologist
Neuropsychiatric
Neurostimulation
Neurotoxic
Nilotinib
Nursing
Opioids
Parkinson
Parkinson Disease
Pathology
Pathophysiological
Pharmacodynamics
Prion
Progressive
Receptors
Stress
Supraspinal
Symptom
Tremor
Tyrosine Kinase Inhibitor
Waveform

Semantics

Type Source Name
gene UNIPROT IMPACT
disease MESH cognitive impairment
disease MESH movement disorders
disease MESH neurological disorders
disease MESH chronic pain
disease MESH cerebral ischemia
disease DOID dystonia
disease MESH tremor
disease MESH multiple sclerosis
disease DOID multiple sclerosis
disease MESH Parkinson disease
disease DOID Parkinson disease
disease MESH cancer
disease DOID cancer
gene UNIPROT AKR1A1
gene UNIPROT ARMC9
drug DRUGBANK Nilotinib
drug DRUGBANK Dopamine
gene UNIPROT DDR1
disease MESH inflammation
disease DOID dementia with Lewy bodies
drug DRUGBANK Manganese
gene UNIPROT FYN
gene UNIPROT SYNM
disease MESH neurodegenerative disorders
disease DOID synucleinopathies
drug DRUGBANK Huperzine B
gene UNIPROT ELAVL2
disease MESH depression
gene UNIPROT MAGEE1

Similar

Leave a Comment

Your email address will not be published. Required fields are marked *